Esketamine on Postpartum Depression in Cesarean Section Women

Completed 336 enrolled Ailin Luo Jingmen No.1 People's Hospital · collab Maternal and Child Health Hospital of Hubei Province · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

Timeline

Start: 2021-05-01
Primary completion: 2024-03-31
Completion: 2024-03-31

Outcome

Met primary endpoint

paper The total incidence of PPD in the esketamine group (11.59%) was significantly less than the control group (20.89%) PMID 41607308 ↗

Publications

Chu T, Peng X, Wan K, Li M, Liu T, Shi X, Yao W, Li S, Zhou Z, Yang C, Xu H, Kong J, Wang C, Cheng J, Xu Z, Li D, Liu X, He J, Ye X, Luo A, Xu A, Gao F. Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. Eur J Anaesthesiol. 2026 Jul 1;43(7):584-593. doi: 10.1097/EJA.0000000000002348. Epub 2026 Jan 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Esketamine	Other / unclassified	80 mg	Intravenous